Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War

Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Other Events. Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax ® (Anthrax Vaccine Adsorbed) to the U.S. Department of War GAITHERSBURG, Md., Nov. 04, 2026 (BUSINESSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a

Event · Contract
Role
supplier
Counterparty
U.S. Department of War
Value
$22.3 million
Duration
remaining deliveries are expected in 2027

Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.

Original reporting
Published Nov 4, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$EBS
Bullish
high confidence
Mentioned
$EBS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$EBSBullishMed
01

Why it matters

The $22.3 million order modification provides a near‑term revenue boost and underscores the company's strategic role in national security.

02

Market read

The announcement may lift EBS modestly while highlighting continued government demand for biodefense products.

03

What to watch

Potential supply chain constraints or future budget cuts could limit subsequent deliveries.

Relevance 6/10Novelty 7/10Timing: post‑market today

Background

Emergent BioSolutions is a leading provider of biodefense vaccines, with BioThrax being the only FDA‑approved anthrax vaccine in the U.S.

Company-level read

Ticker impact

$EBSBullishHigh confidence
Context

Emergent BioSolutions disclosed a $22.3 million contract modification to supply BioThrax to the U.S. Department of War, with the first $7.4 million delivery this year.

Expected impact

likely modest upside as investors price in the additional revenue stream

Evidence & confidence

The contract is a fresh, material government award that directly boosts near‑term earnings expectations.

Market effects

Strengthens outlook for defense and biodefense stocks as government spending on bio‑threat countermeasures rises.

Limited to U.S. defense contractors; minimal broader market effect.

Reinforces confidence in U.S. government contracts for biotech firms globally.

Counterpoint

The contract size is modest relative to the company's market cap; investors may already price it in.

Key entities

  • Emergent BioSolutions Inc.

    U.S. biotech firm supplying BioThrax anthrax vaccine to the Department of War.

  • U.S. Department of War

    Federal customer receiving the vaccine under an IDIQ contract.

Related articles

$EBSMedAI 8/10

Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs

Emergent BioSolutions reported Q3 2026 revenue of $110M, down from $231M in Q3 2025 due to MCM delivery timing. Adjusted EBITDA was -$5M, with adjusted gross margin at 28%. Full-year 2026 revenue guidance was updated to $600M-$645M. The company faces competitive pricing pressure in the naloxone market and expects MCM revenues to decline. CFO Richard Lindahl is retiring, and net leverage remained stable at 2.4 times.

$EBSMedAI 8/10

Emergent BioSolutions 2026: Revenue $110M, EPS ($0.64) — 10-Q Summary

Emergent BioSolutions reported Q3 2026 revenue of $110M, a 52.4% YoY decline, and a net loss of $32.7M, compared to a profit of $51.2M a year earlier. Nine-month revenue fell 16% to $500.4M, driven by lower NARCAN sales and declines in medical countermeasure products. The company reduced its workforce by 90 employees in August to cut costs.

$EBSMed

Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript

Emergent BioSolutions reported Q3 2026 revenue of $110M, within guidance, bringing YTD revenue to $500M. Adjusted EBITDA reached $128M (25% margin), with $122M in operating cash flow. The company highlighted progress in its transformation plan, including contract modifications and international sales. CFO Rich Lindahl announced his retirement, with Frank Vargo assuming the role in 2027. The company also discussed its role in biodefense and AI partnerships for clinical development.

$EBSMed

Emergent Biosolutions Q3 Earnings Call Highlights

Emergent Biosolutions reported Q3 cash of $176M, reduced gross debt by $179M YoY, and repurchased $75M in bonds. MCM revenue was $59M, with international sales contributing $72M. Naloxone market faced competition. 2026 revenue guidance updated to $600M-$645M. CFO to retire, interim replacement named. (EBS)